Group items tagged

This notice announces the opportunity to apply for funding under the National Genetics Education and Family Support Program (NGEFSP). The purpose of this program is to increase access to genetic services by promoting and strengthening engagement of individuals and families with, or at risk for, genetic conditions in the genetic health care delivery system.This will be accomplished by funding a program that will: * provide culturally- and linguistically-appropriate education and resources on genetics and genetic conditions to families; * provide support for individuals and families with, or at risk for, genetic conditions so that they can be equal partners in their health care; * train individuals and families with, or at risk for, genetic conditions to become family leaders within the genetic health care delivery system and the Regional Genetics Networks (RGNs); and * provide technical assistance to RGNs on how best to incorporate family leaders into their programs and reach underserved populations.1

This Funding Opportunity Announcement (FOA) seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates.  Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field.  Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and cessation of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies. 

This Funding Opportunity Announcement (FOA) seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course, and outcomes of substance and alcohol use disorders (SUDs). Previous work in genetic epidemiology and molecular genetics has established that SUDs are highly heritable, developmental disorders with important genetic substrates.Building on these findings, new studies using genetically informative approaches are needed to elucidate the complex interplay of genetic and environmental factors in developmental trajectories of SUDs and comorbid conditions, deepen and refine phenotypic definitions of SUDs, and meet the methodologic challenges of the field.Such studies hold great potential to promote understanding of the true contributions of both genetic and environmental factors to initiation, progression, comorbidity, adverse outcomes, and cessation of SUDs; to elucidate mechanisms of risk; and to enhance opportunities for translation to treatment, prevention, gene-finding and molecular studies.

Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

The National Institute on Alcohol Abuse and Alcoholism is publishing a Funding Opportunity Announcement (FOA) to seek applications on novel genetic mechanisms underlying the development of tolerance and the progression to alcohol use disorder. Alcohol use disorders are complex, multifactorial, and influenced both by genetic and environmental factors. The purpose of this FOA is to stimulate and support efforts on identifying genetic, genomic and epigenetic factors contributing to the development of sensitivity and tolerance to alcohol.

There are two main purposes of the Rat Opioid Genome Project. The first is to tease out genetic, genomic, and molecular (epi)genetic variants that underlie phenotypes associated with distinct stages along the opioid use disorder (OUD) trajectory to identify potential targets for future interventions at early stages along the trajectory. The second is to identify genetic, genomic, and molecular (epi)genetic variants underlying comorbid conditions and/or phenotypes that can be used to develop therapeutics to save lives of people who are at the end stages of the OUD trajectory.

 The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD.  The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD.  However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains.  The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members.  Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC.  Multi-site clinical trials will not be considered responsive to this FOA. Also listed under R21

Epidemiological studies have shown that psychiatric disorders, constitute a significant public health burden across diverse populations worldwide. These mental disorders are characterized by marked genetic heterogeneity, with both common and rare variation contributing to the complex phenotypic outcomes. For reasons such as population homogeneity and ease of ascertainment, most genome-wide genetic studies to date have mainly focused on cohorts of European-ancestry, however, no single population is sufficient to fully uncover the variants underlying neuropsychiatric diseases in all populations. The absence of diverse ancestries in genome-wide association studies has therefore negatively impacted their ability to illuminate the full genetic architecture of complex neuropsychiatric traits. Populations with different ancestral origins vary in terms of allele frequencies, biological adaptations, and other properties that affect the detectability and importance of risk variants. Lack of ancestrally diverse genome-wide data can lead to the misidentification of causal variants due to cryptic population stratification or simply overlooking a causal variant altogether, since rare variants are likely to be more recent in origin and more geographically localized.

This notice announces the opportunity to apply for funding under the Advances in Integrating Genetics into Clinical Care (AIGCC) program. The purpose of this program is to serve as a national resource on the use of genetic and genomic information in clinical practice for genetic service providers, primary and specialty health care providers, and families. The program will accomplish this by implementing the priorities below.

Through this Funding Opportunity Announcement (FOA), the National Institute of Mental Health (NIMH) seeks applications to develop, sustain, enhance, and enrich a centralized national biorepository for genetic studies of psychiatric disorders for facilitation and acceleration of the scientific understanding of the genetic risk architecture underlying mental disorders. This effort is expected to involve a functionally integrated, multi-disciplinary team that will provide for open sharing of biosamples and data resources through a single, centralized, national resource to advance basic and translational research in the genetics of mental disorders.

This Funding Opportunity Announcement (FOA) issued by the National Institute on Alcoholism and Alcohol Abuse (NIAAA), solicits cooperative agreement (U10) applications focusing on studies that (i) identify genetic variants that affect the susceptibility to develop alcohol dependence in adult and adolescent populations, (ii) determine molecular and functional mechanisms of these variants, (iii) identify and characterize gene x gene and gene x environment interactions leading to alcoholism, (iv) develop and refine phenotypes that will facilitate genetic analysis. (v) perform prospective studies of COGA probands.

Genetic and genomic studies have identified genes and gene variants that may impact the fundamental biological mechanisms underpinning substance use disorders (SUDs).  Discovery of these genes/variants, while extremely valuable, is only the first step in understanding the molecular processes that influence SUDs. This Funding Opportunity Announcement (FOA) encourages basic functional genetic and genomic research in two areas:  1. functional validation to determine which candidate genes/variants/epigenetic/non-coding RNA features have an authentic role in SUDs, and 2. detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in SUDs.   

The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.

This Administrative Supplement Program intends to support gene function studies in collaboration with the NIH Undiagnosed Diseases Program (UDP) to investigate the underlying genetics, biochemistry and pathophysiology of newly diagnosed diseases identified through the UDP. In recent years, gene function studies combined with genetic and genomic analyses and metabolic studies have greatly improved diagnoses of these very rare diseases and advanced scientific knowledge of the underlying pathogenesis. This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact.

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.   

he overall goal of this initiative is to enhance our understanding of fundamental biological mechanisms involved in disease conditions that disproportionately affect health disparity populations and develop therapies or interventions that can directly or demonstrably contribute to the reduction or elimination of health disparities. This funding opportunity announcement (FOA) solicits applications to conduct: 1. Biological and genetic research to explore disease mechanisms or pathways that influence health outcomes in minority and health disparity populations. 2. Clinical and translational research linking basic science discovery with effective treatment or clinical practice to improve health outcomes in minority and health disparity populations. Projects investigating the etiology, physiology, genetic risk factors, molecular pathways, gene-environmental interactions, pharmacogenomic and personalized medicine in health disparity populations are particularly encouraged.

This funding Opportunity Announcement (FOA) encourages Multiple Principal Investigator (Multi-PD/PI) applications from United States (U.S.) and Indian institution as bilateral collaborations that will advance science and technology important to understanding, preventing, and treating blinding eye diseases, visual disorders, and their complications. Areas of Research Collaboration: Applications are encouraged from organization/institutions that propose to conduct research on the basic biology and/or genetics of ophthalmic diseases through collaborations with Indian investigators on the following: diabetic retinopathy, glaucoma, age-related macular degeneration, retinitis pigmentosa, including rare and genetic diseases such as congenital cataracts, as well as other eye conditions such as ocular inflammation/uveitis, refractive error, low vision, and corneal injury. Basic, translational, or epidemiological research maybe proposed. Clinical trials will not be supported under this FOA.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative) that is intended to accelerate cancer research. The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/prevention-screening-working-group-report.pdf) Recommendation G (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel#ui-id-3 ): "Sponsor initiatives to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development and conduct implementation science research to accelerate development, testing, and broader adoption of proven strategies to significantly reduce cancer risk and address cancer health disparities in these areas." This Funding Opportunity Announcement invites U01 applications for projects that develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer so that they can make informed clinical risk management decisions.

Since its inception in 1958, the Hearing Health Foundation has supported hearing and balance research elucidating the etiology, diagnosis and treatment, genetics, normal and abnormal function, mechanisms, and development of animal models. As the largest nonprofit funder of hearing and balance research, HHF awards emerging researchers grants to stimulate research that leads to a continuing, independently fundable line of research. As part of this mission, the foundation is seeking applications for new avenues in a number of areas of hearing and balance science, including central auditory processing disorders, hearing loss in children, hyperacusis, Meniere's disease, stria, tinnitus, and Usher syndrome. HHF also encourages applications in the areas of general hearing health, including the physiology of hearing and balance; the epidemiology of auditory and vestibular disorders; human otopathology; the diagnosis, treatment, and prevention of hearing loss and balance disturbance; human genetics and mouse models of peripheral and central auditory/balance dysfunction; innovation in cellular and molecular therapies; and auditory and vestibular implants and hearing aids.

The purpose of this FOA is to fund research centers that will establish longitudinal cohorts in rare HLBS diseases to investigate unaddressed research questions using epidemiologic study designs and methods that are appropriate for conditions affecting fewer than 200,000 persons in the US. These observational cohort studies should be designed to provide an evidence base for future interventional studies, including clinical trials; for developing better diagnostics than those that are currently available; for answering early translational questions; or for broader implementation of guidelines for managing these diseases. This program will provide opportunities to advance rare disease research using genetics and deep phenotyping to characterize the disease and to identify disease sub-types; to use data science methods that integrate clinical and patient-reported outcomes (PROs) with laboratory, imaging, environmental and -omics data to understand the natural history of disease; to generate data that differentiate patients with the same morphological phenotype but different genetic mutations and severity of outcomes; to elucidate genotype-phenotype interactions and multisystem phenotyping to develop reliable and valid predictive tools to determine who will respond to which treatments and when to intervene; and to encourage innovative methods such as telemedicine to include participants with rare diseases located in remote locations.